Directions for the improvement of dendritic vaccines for HER2-positive breast cancer

Abstract

Breast cancer is the disease with the largest number of diagnoses at present, which seriously threatens the health of women all over the world. HER2 positive breast cancer is one of the subtypes, accounting for 25% -30% of breast cancer cases. Despite good progress in chemotherapy, radiation therapy, endocrine therapy and other areas, cancer recovery remains a huge challenge. The development of tumor therapeutic vaccines is a promising strategy. In recent years, more and more vaccines based on different carrier platforms have gradually been discovered. These vaccines stimulate the immune system of patients to produce specific immune responses, thereby reducing the recurrence and metastasis rate of cancer. However, in current clinical research evaluations, no type of vaccine has demonstrated significant therapeutic effects. This paper summarizes the mechanism and types of DC vaccine for HER2 positive breast cancer, analyzes its shortcomings according to relevant clinical trials, and proposes solutions in some aspects such as action target, delivery vector, combined immunity, etc, provides a reference for the development and improvement of therapeutic vaccine for breast cancer in the future. At present, many studies are addressing the problems with some vaccines, and there will be better therapeutic vaccines for breast tumors applied in clinical practice in the future, benefiting all humanity.